Gout Treatment and Comorbidities in a Large US Population
Author Information
Author(s): Paola Primatesta, Estel Plana, Dietrich Rothenbacher
Primary Institution: Global Clinical Epidemiology, Novartis Pharma AG
Hypothesis
How do comorbidities affect gout treatment patterns and flare frequency?
Conclusion
Comorbidities significantly influence gout treatment patterns and increase the risk of acute attacks.
Supporting Evidence
- More than half of gout patients had comorbidities, affecting treatment.
- Patients with cardiometabolic comorbidities were more likely to receive anti-gout prescriptions.
- 39% of patients did not receive any prescription medication for gout.
Takeaway
This study looked at gout patients and found that many have other health problems that make their gout worse and affect how they are treated.
Methodology
Retrospective cohort study using the PharMetrics Patient-Centric Database to analyze gout patients with at least 2 claims for diagnosis and related prescriptions.
Potential Biases
Potential underreporting of flares as many patients may self-manage without consulting a physician.
Limitations
Findings may not be generalizable to patients without commercial insurance; gout diagnosis was not confirmed by medical record review.
Participant Demographics
Mean age 55.2 years; 75.6% male; 58.1% had comorbidities.
Statistical Information
P-Value
p<0.0001
Confidence Interval
1.48-1.74 for women; 1.06-1.13 for men
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website